FDA approves Kalydeco treatment for patients as young as 4 months old
The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) as a treatment for infants as young as four months with Cystic Fibrosis caused by certain mutations, making it the first drug to target the underlying cause of CF and has been approved for such young ages.
“Initiating therapy as early as four months of age may have the potential to modify the course of the disease” said Margaret Rosenfeld, of the University of Washington School of Medicine. JP Clansy, vice president at the Cystic Fibrosis Foundation said that: “We believe that people with CF will experience the maximum benefit from these therapies when they begin treatment early in life, before the disease has caused significant damage.”
CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Normally, the CFTR protein functions as a sort of “gate” on the surface of cells that can open and close to control the movement of chloride ions, but in CF, the mutated protein does not function properly. Kalydeco is a CFTR modulator that works to correct the underlying defect in the CFTR protein. Specifically, Kalydeco is a CFTR potentiator because it works on CFTR proteins where the “gate” has become “stuck” and remains “closed.” By opening the gate, Kalydeco eases the transport of chloride ions and water in and out of cells.
“Since the initial approval of Kalydeco more than eight years ago, we have continued to advance our clinical development program with the goal of treating the underlying cause of cystic fibrosis as early in life as possible,” said Reshma Kewalramani, Vertex’s CEO and president. “Today’s approval is a testament to our relentless efforts, alongside the clinical and scientific community, to reach all people with CF who may benefit from our medicines,” she added. The new approval was based on data from the Phase 3 open-label clinical trial. This trial included six CF infants from the age of 4 months up to 6 months, who were treated with Kalydeco. Safety data in these young children were consistent with what has been reported in other age ranges. “Our hope is that those who start on modulators as infants may never experience many of the classic symptoms of CF, and we are committed to supporting ongoing research to better understand the impact of early treatment,” Clancy said.